Publications
- Safety of vedolizumab and ustekinumab in the treatment of pregnant women with inflammatory bowel disease - a multicentre retrospective-prospective observational study2022 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Severe acute hepatitis and acute liver failure of unknown origin in children: a questionnaire-based study within 34 paediatric liver centres in 22 European countries and Israel, April 20222022 | Second Faculty of Medicine
- Impact of anti-TNFα exposure in utero on the development of immune systems of exposed children - A controlled, multicentre observational study2018 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre2017 | First Faculty of Medicine
- Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort2017 | First Faculty of Medicine
- Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis2016 | First Faculty of Medicine, Second Faculty of Medicine
- Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis2024 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations2024 | First Faculty of Medicine, Second Faculty of Medicine
- Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?2023 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis2023 | Second Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...
